GSK bets $1.3B on KRAS-EGFR conjugate from HUTCHMED
GSK has licensed ex-China rights to HUTCHMED’s HMPL-A830, an experimental antibody conjugate that delivers a KRAS inhibitor to EGFR-expressing tumors, in a deal worth up to $1.295 billion (€1.12 billion). The preclinical asset is expected to enter the clinic this year.
Why it matters: The deal gives GSK a new way into KRAS, one of oncology’s hottest but hardest targets, while strengthening its expansion into lung and gastrointestinal cancers. It also puts GSK into an emerging race to package KRAS inhibitors inside tumor-targeting antibodies — an approach designed to attack resistance while limiting the systemic toxicity of KRAS blockade.
By the numbers: GSK will pay Chinese biotech HUTCHMED $110 million (€95 million) upfront, with another $1.185 billion (€1.02 billion) tied to development, regulatory and commercial milestones, plus tiered royalties. HUTCHMED retains rights in mainland China, Hong Kong, Macau and Taiwan. GSK also secured a right of first negotiation on another earlier-stage candidate from HUTCHMED’s antibody-targeted therapy conjugate (ATTC) platform.
How it works: HMPL-A830 links an anti-EGFR antibody to a small-molecule KRAS inhibitor. The antibody is intended to ferry the payload preferentially into EGFR-expressing tumors while itself blocking EGFR signaling.
- That combination is particularly relevant in colorectal cancer. Blocking KRAS can trigger compensatory EGFR signaling upstream, allowing the MAPK growth pathway to switch back on. Combining KRAS and EGFR inhibition is therefore already clinically validated: Bristol Myers Squibb’s Krazati (adagrasib) plus cetuximab received accelerated FDA approval for KRAS G12C colorectal cancer in 2024, followed by full FDA approval of Amgen’s Lumakras (sotorasib) plus Vectibix (panitumumab) in January 2025.
- HMPL-A830 attempts to put both mechanisms into a single molecule and concentrate the KRAS inhibitor in the tumor. HUTCHMED argues that could permit stronger or more sustained KRAS inhibition with less on-target toxicity in normal tissues, although that remains a preclinical hypothesis. The company has not disclosed in today’s announcement which KRAS mutations the payload targets.
What they’re saying: “HMPL-A830 is our third drug candidate from these novel payload platforms and the
first from our platform to be licensed to a global partner, following two candidates that have entered clinical
development,” said Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer of
HUTCHMED.
The competition: HUTCHMED’s “first-in-class” claim related to HMPL-A830 will have to be proven.
- Fellow Chinese biotech Jacobio Pharmaceuticals is developing JAB-BX600, an EGFR-targeted conjugate carrying its KRAS G12D inhibitor JAB-22G82. Preclinical data presented in July showed tumor regression in colorectal and pancreatic cancer models, and Jacobio plans to file an IND in the second half of 2026. That puts the two programmes on broadly parallel timelines, although HMPL-A830 has already received IND clearance in China and the US.
- Jacobio’s programme is specifically aimed at KRAS G12D. HUTCHMED has so far described HMPL-A830 only as carrying a “highly selective and potent KRAS” inhibitor, leaving its mutation coverage — potentially an important point of differentiation — undisclosed.
The big picture: HMPL-A830 also fits a much broader rebuild of GSK’s solid tumor portfolio.
- The UK pharma has historically been stronger in blood cancers and women’s cancers, but is explicitly expanding into lung and gastrointestinal tumors. Its biggest move came this summer with the $10.6 billion acquisition of Nuvalent, bringing late-stage ROS1 and ALK inhibitors and an earlier HER2 programme into its lung cancer franchise.
- GSK is simultaneously advancing two externally sourced antibody-drug conjugates: B7-H3-targeting Ris-Rez, already in Phase 3 and recently backed by positive survival data in lung cancer, and B7-H4-targeting Mo-Rez in gynecological tumors. Both are licensed from China-based Hansoh Pharma. Its pipeline also includes velzatinib, a KIT inhibitor being moved into Phase 3 for gastrointestinal stromal tumors.
- HMPL-A830 therefore adds both another conjugate and another precision small-molecule mechanism — essentially combining two areas where GSK has been investing heavily.
What’s next: HUTCHMED will run the initial global study, with development initially targeting colorectal, pancreatic and lung cancers. The registered Phase 1/2 trial plans to enroll 147 patients, with GSK taking responsibility for subsequent development outside Greater China.
